 Organogram is the latest cannabis company to list at the Nasdaq, and that is a hard bridge to cross because very few cannabis companies have been able to list here at the Nasdaq. Joining me now is the CEO and the CFO of Organograms, Greg Engel and Paolo DeLuca. So Craig, why did you want to come to the Nasdaq? Yeah, I mean certainly we had seen a big influx and change to our investor base where we were getting many more U.S. investors trading on the OTC and the QX. And then as we've been meeting with investment funds through the U.S., we're all seeing a shift in terms of large funds and more traditional kind of long only funds that we're looking to invest in us and looking to invest in the space. But we're unable to do so until we're list on one of the major exchanges. So we saw a phenomenal opportunity to join the Nasdaq and become part of that family because really we're a company that's really focused on technology and innovation and the Nasdaq is really founded on technology and innovation. So a great opportunity for us and so far on day one, great response from investors. You just recently made a big investment in a chocolate company. We know that the edible market is going to be coming up in Canada fairly soon at the end of the year for adult use. Why chocolate? Why not gummies or some other form factor? No, it's a great question. So we've invested in chocolate technology ourselves actually. So we're kind of put a $15 million investment into kind of purchasing and acquiring the leading systems for developing chocolate. When we look at US state data, for example, with Colorado, we see that when the edible form is chocolate is definitely one of the leading, if not the leading form consistently. And we have a team that really has a long history of working in chocolate across a couple of different companies. So we saw it as an area where a company that focuses on premium product and we saw it as a way to differentiate ourselves with a premium line and a mainstream line of really the best quality chocolate we could bring to market and having that capability with leading innovative equipment allows us to produce a broad range of chocolates and really allows us to bring something unique and different. When we go into a category, we want to have a strong ownership position of that category and have a big portion of it. So that's why we chose chocolate as one that we think we can dominate in. And what about the CBD category? You recently said comments about supply and issues there. What is the situation on that? Yeah, like we're seeing here in the US in the Canadian market, there's overwhelming demand for CBD. And so the difference being in Canada where CBD is still very much restricted to licensed producers like Organogram and we're able to access CBD from hemp in Canada. But certainly until just last year, we didn't see much of that produced. So we actually formed a partnership with a company in Canada called 1812, which has a very high CBD hemp. They harvested last year. So we're processing 6,000 kilos of that product to convert it into pure CBD product to bring to the market in the near term. And we're looking to expand that relationship for 2019 because there's a huge demand for CBD in the market. You've accomplished something that not a lot of cannabis companies have accomplished. And that is you've had positive EBDA for three consecutive quarters. What is it that you're doing as a company that these other companies are not accomplishing? Yeah, maybe I'll start off and answer that and then turn over to Paula. But we differentiate ourselves by being the largest indoor production facility in the world versus greenhouses. And so being an indoor producer, we can control our environment day in and day out and we produce a high quality product. We did that to focus on quality, but ultimately our yields are so high that it impacted costs. So maybe I'll let Paula answer that a bit further. Great. Thanks. So our cash cost of cultivation is 65 cents last quarter, all in cost, including share base compensation and depreciation was 85 cents a gram. That's the cheapest in the space from what we can derive from looking at other comparables in the space. We've actually hit a lower number than that even in the previous quarter. So when you take that as your base cost and then you have some packaging and some shipping they get that on top of that, we're still by far the lowest in the space. And then because we're producing an indoor product, we're able to generate an average selling price that's in the medium to high range. On top of that, our SG&A is under control, which is a big difference compared to other companies. Other companies in many cases are spending more in SG&A than they have in revenue. Our last quarter was 21%, which is a reduction from 36% in the previous quarter. So I think all those factors together allow us to generate the adjusted EBITDA that we have. Just being solid, being conservative, not spending like drum concealers. Just running it like a real business, to be honest with you. That's our objective. I mean, we're building a long-term sustainable business here, but we feel it's important to have positive gross margin, positive adjusted EBITDA today. And we want to, I think that highlights to investors the stewardship of us as a company and leaders. Great. Well, it's an exciting time for you guys. Congratulations. That is Organigram here at the NASDAQ. And I'm Deborah Borja reporting for the Green Market Report.